Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel

Cushen, S.; Power, Derek G.; Murphy, Kevin P.; McDermott, Ray; Griffin, Brendan T.; Lim, Marvin; Daly, Louise; MacEneaney, Peter; Sullivan, Kathleen O'; Prado, Carla M.; Ryan, Aoife M.

doi:10.1016/j.clnesp.2016.04.001

Cited by 78 publications

(112 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors speculate that obesity may lower the risk because these men had not developed cachexia yet. Similar results were seen amongst 55 men with mCRPC in Korea and 63 men with mCRPC in Ireland . However, a later study, including 1 006 men with mCRPC participating in a phase III international clinical trial, found BMI was not associated with overall survival .…”

Section: Introductionsupporting

confidence: 65%

“…In a small study of 55 Korean patients with mCRPC who received docetaxel, a higher BMI (≥23 kg/m 2 ) was associated with decreased PCSM . A report from a small study of 63 Irish patients with mCRPC, where BMI was cut at 25 kg/m 2 , found that higher BMI was a significant predictor of longer overall survival . Thus, the literature to date suggests that unlike localised disease, for men with mCRPC obesity is associated with similar or better overall survival.…”

Section: Discussionmentioning

confidence: 99%

“…It is now well established that obesity is associated with aggressive prostate cancer and worse long‐term outcomes amongst patients with localised prostate cancer . However, only a few studies have assessed the link between BMI and prostate cancer outcomes amongst men with mCRPC , and all found BMI was associated with similar or better survival. However, no study to date has investigated the association between obesity and long‐term prostate cancer outcomes amongst men with non‐mCRPC.…”

Section: Discussionmentioning

confidence: 99%

“…Although a few studies have analysed the effects of obesity and prostate cancer outcomes amongst patients with metastatic castration‐resistant prostate cancer (mCRPC) , there is not a single published study on obesity and long‐term prostate cancer outcomes among non‐mCRPC cases. Halabi et al analysed data from 1 296 men with advanced metastatic prostate cancer who were enrolled in nine prospective clinical trials conducted by the Cancer and Leukemia Group B (CALGB).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Obese patients with castration‐resistant prostate cancer may be at a lower risk of all‐cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Obese patients with castration‐resistant prostate cancer may be at a lower risk of all‐cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Low BMI and WL percentage, independently, anticipate a global survival rate (Arends et al, 2017), which is a strong predictor of mortality by cancer (Cederholm et al, 2015;Hong, Yi, Yi, Hong, & Ohrr, 2016). However, Cushen et al (2016) reported that parameters such as BMI do not predict clinical results, because they do not precisely distinguish the loss of lean and fat mass, neither describe each tissue. Brewczyński et al (2017) reported similar statement.…”

Section: Discussionmentioning

confidence: 99%

Association between weight loss and clinical-pathologic factors in oncological patients in chemotherapy treatment: a longitudinal study

Pinheiro

Benincá²,

Mazur

et al. 2019

Acta Sci. Health Sci.

View full text Add to dashboard Cite

The present work aimed to study the relation between weight loss (WL) and clinicalpathologic factors in patients under chemotherapy treatment. It was a longitudinal observational study performed with patients assisted in an oncological ambulatory. The sample was composed of 402 patients, with an average age of 58.4 ± 13.6 years, of which 56.5% were women, and 51.7% were elderly. Regarding tumor localization, 12.9% were found in the head and neck, 22.6% in the breast, 10.2% in the lungs, 29.4% in the gastrointestinal tract (GI), and 24.9% in other body parts. A gradual fall of nutritional state in relation to BMI was observed, and the patients were advancing to malnutrition. When correlating the severe and non-severe weight loss (WL) with anthropometric data, a significant difference was obtained (p < 0.05). The overweight and obese patients had a greater severe WL in relation to the eutrophic and low weight group (p < 0.05). However, 67.3% of patients presented WL and a following nutritional state alteration, with the GI tract cancer presenting a significant difference, 37.4% (p < 0.05), in addition to severe WL (p < 0.000). Patients diagnosed with cancer, especially in the GI tract, and treated with chemotherapy, have higher chances of WL, which triggers a reduction of survival rate, with obesity and age being reliable predictors of a consequent severe WL.

show abstract

Body Composition, Inflammation, and 5-Year Outcomes in Colon Cancer

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Obesity, particularly visceral obesity and sarcopenia, are poor prognostic indicators in colon cancer. OBJECTIVES To explore the association between body composition profiles and 5-year colon cancer outcomes and delineate the associated underlying inflammatory processes. DESIGN, SETTING, AND PARTICIPANTS This multicenter translational cohort study included patients with nonmetastatic colon cancer who did not have underlying chronic inflammatory disorders and were not receiving anti-inflammatory drugs referred to tertiary cancer centers from 2009 to 2015. Preoperative acute phase proteins (white cell count, C-reactive protein, and albumin), cytokines (interleukin [IL]-1b, IL-2, IL-6, IL-10, interferon γ, and tumor necrosis factor α), vascular endothelial growth factor (VEGF), and cell surface receptor expression levels (CD11b and CD14) were measured. All patients underwent follow-up for at least 5 years. Data were analyzed in December 2020. EXPOSURE Nonmetastatic colon cancer. MAIN OUTCOMES AND MEASURES The associations of body composition profiles with 5-year cancer recurrence and disease-specific mortality were analyzed using Mantel Cox log-rank test and Kaplan-Meier curves. RESULTS A total of 28 patients were included (median [interquartile range] age, 67 [58-72] years;22 [78.6%] men). Low skeletal muscle area (SMA) and high visceral to total fat ratio were associated with poor clinical and oncological outcomes, including increased 5-year recurrence (low SMA: hazard ratio [HR], 2.30 [95% CI, 1.41-2.89]; P = .04; high visceral to total fat ratio: HR, 5.78 [95% CI, 3.66-7.95]; P = .02). High visceral to total fat ratio was associated with increased 5-year disease-specific mortality (HR,5.

show abstract

Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel

Cited by 78 publications

References 37 publications

Obese patients with castration‐resistant prostate cancer may be at a lower risk of all‐cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

Obese patients with castration‐resistant prostate cancer may be at a lower risk of all‐cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

Association between weight loss and clinical-pathologic factors in oncological patients in chemotherapy treatment: a longitudinal study

Body Composition, Inflammation, and 5-Year Outcomes in Colon Cancer

Contact Info

Product

Resources

About